Abstract
A review of the patent literature encompassing the past 3 years (~ 2000 – 2003) in the area of bone anabolic therapies for treatment of osteoporosis and related diseases is described. A variety of potential therapeutics are covered, as well as improvement attempts on the first approved bone anabolic agent, recombinant human parathyroid hormone (rPTH; teriparatide, Forteo®, Eli Lilly & Co.). The patent literature suggests that multiple strategies are currently being pursued in order to deliver the first orally bioavailable anabolic agent to the market and that a variety of new targets are also being evaluated for further development.